Gyre Therapeutics, Inc.GYRENASDAQ
Loading
Operating Income ContractionContracting
Percentile Rank93
3Y CAGR+7.7%
Studio
Year-over-Year Change

Profit from core business operations before interest and taxes

3Y CAGR
+7.7%/yr
Annual compound
Percentile
P93
Near historical high
vs 3Y Ago
1.2x
Modest growth
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$11.49M-28.9%
2024$16.16M+124.0%
2023$-67.23M-830.5%
2022$9.20M+111.0%
2021$-83.73M-45.9%
2020$-57.37M-0.2%
2019$-57.28M-69.3%
2018$-33.82M-55.0%
2017$-21.82M-6.9%
2016$-20.42M-